July 1 Quick Takes: Amgen gains on court win; plus Hua, J&J, argenx, Seattle Genetics-Genmab, Interprotein

Appeals court upholds Enbrel patents
Amgen Inc. (NASDAQ:AMGN) shares rose 8% Wednesday, adding more than $11 billion to the company’s market cap, after the U.S. Court of Appeals for the Federal Circuit upheld a 2019 district court decision affirming the validity of two patents covering autoimmune drug Enbrel etanercept.

Read the full 489 word article

How to gain access

Continue reading with a
two-week free trial.